Cannabis Blog

CBD: The Cinderella Molecule

Category: Medical Marijuana | Posted on Fri, February, 17th 2017 by THCFinder

“This changes everything!”

That was the immediate reaction of Bay Area journalist Fred Gardner as he stood in the office of Steep Hill Laboratory in Oakland and eyed a chromatogram showing the unusual cannabinoid content of a hitherto unknown marijuana strain. The year was 2009, and the strain of interest, an oddity called Soma A-Plus, didn’t top the charts for THC (tetrahydrocannabinol), a.k.a. the high-causer, unlike the several thousand other bud samples that Steep Hill had previously tested for California’s medical marijuana dispensaries and growers.

Soma A-Plus was the first of a handful of soon-to-be-discovered strains imbued with a significant amount of cannabidiol (CBD), a compound with intriguing medical properties. One of these strains, Women’s Collective Stinky Purple, tipped the scales at over 10 percent CBD by dry weight, with little THC. This genetic anomaly wasn’t hemp—it was a drug plant, a high-resin, CBD-rich marijuana strain brimming with medicated goo. But anyone who smoked it or consumed it as an edible wouldn’t get high, because CBD isn’t psychoactive. In fact, CBD can actually lessen or neutralize the THC high, depending on how much of each compound is in a given strain or product.

Read More:


Recent Articles



Blog Categories

Popular Articles

Latest Offers In Your Area
Recent Blog Posts
Download Our App!
Malibu Beach Physicians
11.4 Miles Away | Malibu,
BRISK DELIVERY 200% 1 Hitter Hydro
29.5 Miles Away | La Puente, West,
BRISK DELIVERY 200% 1 Hitter Hydro
29.5 Miles Away | La Puente, West,
The Ultimate Guide to the Right Vaping Temper
February 20, 2018 | Category: Culture
What strain are you smoking on today?
December 31, 2017 | Category: Fun
Town Swaps Chocolate for Marijuana and Sees R
December 31, 2017 | Category: News
Mobile Apps
Copyright 2018
All Rights Reserved.
Dispensaries      Strains      About Us      Friends      API / Widgets      Privacy Policy      Terms of Use      Investors      Contact Us